Jan 19 | News
Astellas Pharma Europe Ltd, the European subsidiary of Tokyo-based Astellas Pharma Inc., has appointed Mike Crooks as General Manager of its UK affiliate, Astellas Pharma Ltd. (APL).
|
Jan 19 | News
Jazz Pharmaceuticals has closed its all-stock acquisition of privately held Azur Pharma Ltd., a deal that creates a specialty drug company incorporated in Ireland.
|
Jan 5 | News
Basilea Pharmaceutica Ltd. today announced that it will apply in the second half of 2012 for approval of its antibiotic ceftobiprole in Europe.
|
Dec 5 2011 | News
A wide range of compounds will be made available free of charge to UK medical researchers next year, following a landmark agreement between the Medical Research Council (MRC) and AstraZeneca.
|
Nov 28 2011 | News
Novartis AG said Monday the European Commission has approved Rasitrio, a blood pressure treatment that combines three drugs into one pill.
|
Nov 28 2011 | News
Bristol-Myers Squibb Company and AstraZeneca today announced that the European Commission has approved ONGLYZA(R)(saxagliptin) for use as a combination therapy with insulin (with or without metformin) to improve blood sugar (glycaemic) control in adult patients with type 2 diabetes.
|
Oct 31 2011 | News
Repligen Corporation has announced the execution of a definitive agreement to acquire the business of Novozymes Biopharma Sweden AB in a cash transaction of 17 million euros (~$22.7 million) and future potential milestone payments of 4 million euros (~$5.6 million).
|
Oct 27 2011 | News
Pfizer Inc. announced today that the European Commission has approved the Company's pneumococcal conjugate vaccine, Prevenar 13* (pneumococcal polysaccharide conjugate vaccine 13-valent, adsorbed), for active immunization for the prevention of vaccine-type invasive disease caused by Streptococcus pneumoniae in adults aged 50 years and older.
|
Oct 3 2011 | News
Shares of Human Genome Sciences Inc. fell Friday after a British agency said the country's National Health Service shouldn't cover Benlysta, Human Genome Sciences' new lupus drug.
|
Sep 30 2011 | News
Drug developer Ironwood Pharmaceuticals Inc. said Thursday that its partner Almirall SA has asked European Union regulators to approve its experimental drug linaclotide as a treatment for irritable bowel syndrome.
|